The experience with amyloid PET in AD and NfL in ALS suggests that tau biomarkers might mature to provide sufficient confidence to serve as the basis for accelerated approval and eventually to be surrogate outcomes predictive of clinical benefit [6]. The gene discussed is NEFL; the disease is amyotrophic lateral sclerosis.